---
layout: post
title: "复必泰疫苗已通过中国专家评审"
date: 2021-07-15T09:44:21.422Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20210715-1169264
tags: [ 联合早报 ]
categories: [ 联合早报 ]
---
<!--1626361200000-->
[复必泰疫苗已通过中国专家评审](https://www.zaobao.com/realtime/china/story20210715-1169264)
------

<div>
<p>复星医药昨天（14日）在股东大会上回复投资人问询时表示，中国国家药监局对mRNA冠病疫苗“复必泰”的审定工作已经基本完成，专家评审已经通过，目前正在加紧进行行政审批阶段。</p><p>据财新网报道，“我们和药监局等部门的沟通很顺畅，有关部门对疫苗审批也是一分一秒抓得很紧。”复星医药董事长兼CEO吴以芳说，在供货问题上，复星医药已经与BioNTech提前启动生产准备工作，复必泰疫苗一旦获批，就能第一时间供应到中国。</p><p>知情人士称，未来，复必泰在中国很可能会作为加强针使用，免费接种。</p><section id="imu"><div id="dfp-ad-imu1">        </div></section>      <div id="innity-in-post"></div><div id="dfp-ad-midarticlespecial">        </div>      <a href="https://subscribe.sph.com.sg/promotions/chinese-3-months-99-cents-promotion/?utm_campaign=cn3in199c&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-desktop lazyload  " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-desktop-l_0_1.jpg" alt style="width:100%;" pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-desktop-l_0_1.jpg" referrerpolicy="no-referrer"></a>      <a href="https://subscribe.sph.com.sg/promotions/chinese-3-months-99-cents-promotion/?utm_campaign=cn3in199c&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-mobile lazyload " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-mobile_1.jpg" alt pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-mobile_1.jpg" referrerpolicy="no-referrer"></a>
</div>
